Testing empagliflozin for heart stiffness in hypertrophic cardiomyopathy
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 to 79 years old.
- You have a type of heart muscle disease called non-obstructive hypertrophic cardiomyopathy.
- Your heart muscle is thickened (at least 15mm if no family history, or at least 13mm if family history or genetic cause).
- You are either not diabetic or have type 2 diabetes with a certain blood sugar level (HbA1c between 6.5% and 10.5%).
- You are not currently taking an SGLT2 inhibitor medication (like empagliflozin) or have stopped it for at least 4 weeks.
- You do not have a pacemaker or ICD, and you are not on dialysis or have severe kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if Enavogliflozin, a medication for diabetes, can improve blood flow in the small vessels of the heart and overall heart function in people with obesity or diabetes. You may join if you have obesity or diabetes and have had a recent heart test.
This trial tests a new medication called enavogliflozin (an SGLT2 inhibitor) to see if it helps people with a specific type of heart failure where the heart pumps normally but is stiff. You may be able to join if you have stable heart failure, are not on another SGLT2 inhibitor, and have good kidney function.
This study tests a drug called enavogliflozin to see if it helps people with a specific type of heart failure caused by amyloid buildup. It may improve symptoms and daily function.
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
This trial tests if a diabetes drug can help people with pulmonary arterial hypertension whose right heart function is reduced. Participants take empagliflozin or a placebo for 24 weeks to see if heart function improves.
Hear when a new Nonobstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.